Download PDF
CC BY 4.0 · Arq Neuropsiquiatr 2023; 81(09): 816-824
DOI: 10.1055/s-0043-1772832
Original Article

Brazilian version of the CHOP INTEND scale: cross-cultural adaptation and validation

Versão brasileira da escala CHOP INTEND: adaptação transcultural e validação
Renalli Manuella Rodrigues Alves 
1   Instituto de Medicina Integral Professor Fernando Figueira, Pós-graduação em Saúde Integral, Recife PE, Brazil.
2   Hospital Otávio de Freitas, Departamento de Reabilitação, Recife PE, Brazil.
,
Alessandra Paula de Melo Calado 
3   Hospital Maria Lucinda/Rarus, Serviço de Doenças Raras, Recife PE, Brazil.
4   Universidade Federal de Pernambuco, Centro de Ciências da Saúde, Recife PE, Brazil.
,
Vanessa Van Der Linden 
3   Hospital Maria Lucinda/Rarus, Serviço de Doenças Raras, Recife PE, Brazil.
4   Universidade Federal de Pernambuco, Centro de Ciências da Saúde, Recife PE, Brazil.
,
Maria Aparecida Ferreira Chaves Bello 
4   Universidade Federal de Pernambuco, Centro de Ciências da Saúde, Recife PE, Brazil.
5   Associação de Assistência à Criança Deficiente, Serviço de Fisioterapia, Recife PE, Brazil.
,
Lívia Barboza de Andrade 
1   Instituto de Medicina Integral Professor Fernando Figueira, Pós-graduação em Saúde Integral, Recife PE, Brazil.
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Spinal muscular atrophy (SMA) is a rare genetic disease that causes progressive muscle weakness and impacts motor function. The type I is the most severe presentation and affects infants before 6 months old. In addition, the instruments available for assessing motor function have limitations when applied to infants with neuromuscular diseases and significant muscle weakness.

Objective To translate, cross-culturally adapt, and validate the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) to Brazilian Portuguese.

Methods The present study comprised the translation, synthesis of translations, backtranslation, consolidation by a committee of experts, and test of the final version of the CHOP INTEND in 13 patients with SMA type I. We also assessed the content validity and reliability of the translated version.

Results The scale was translated considering semantic, structural, idiomatic, and cultural aspects. All agreement rates were > 0.8, the overall content validity index of the instrument was 0.98, and inter-rater reliability using the intraclass correlation coefficient was 0.998.

Conclusion The Brazilian version of the CHOP INTEND met semantic and technical equivalence criteria with the original version and was valid and reliable for patients with SMA type I.

Resumo

Antecedentes A atrofia muscular espinhal (AME) é uma doença genética rara que provoca fraqueza muscular progressiva com impacto sobre a motricidade dos pacientes. A AME tipo I é considerada o tipo mais grave e acomete lactentes antes dos 6 meses de idade. As escalas disponíveis para avaliação das aquisições motoras mostram limitações para uso com crianças pequenas com doenças neuromusculares e fraqueza importante.

Objetivo Realizar a tradução, adaptação transcultural e validação para a língua portuguesa do Brasil da Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND, na sigla em inglês).

Métodos O presente estudo seguiu as etapas de tradução, síntese das traduções, retrotradução, consolidação por comitê de especialistas e teste com 13 pacientes com AME tipo 1. Foi avaliada a validade de conteúdo e a confiabilidade do instrumento.

Resultados A escala foi traduzida considerando os aspectos semânticos, estruturais, idiomáticos e culturais. Todas as taxas de concordância foram > 0,8. O índice de validade de conteúdo geral do instrumento foi de 0,98. A confiabilidade interavaliadores analisada através do coeficiente de correlação intraclasse (ICC, na sigla em inglês) demonstrou um valor de ICC = 0,998.

Conclusão A versão da CHOP INTEND em português atende aos critérios de equivalência semântica e técnica em relação à versão original e apresenta validade de conteúdo e confiabilidade para seu uso na população de pacientes com AME tipo I.

Keywords

Muscular Atrophy, Spinal - Growth and Development - Validation Study

Palavras-chave

Atrofia Muscular Espinal - Crescimento e Desenvolvimento - Estudos de Validação

Authors' Contributions

RMRA: conceptualization, methodology, project administration, data collection, formal analysis, writing-original draft, writing-review and editing; APMC, VVDL, MAFCB: data acquisition, drafting of manuscript, critical review; LBA: conceptualization, methodology, formal analysis, writing-original draft, writing-review and editing. All authors discussed the results and contributed to the final manuscript.




Publication History

Received: 03 December 2022

Accepted: 01 May 2023

Article published online:
04 October 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Mercuri E. Spinal muscular atrophy: from rags to riches. Neuromuscul Disord 2021; 31 (10) 998-1003 DOI: 10.1016/j.nmd.2021.08.009.
    CrossrefPubMedGoogle Scholar
  • 2 Farrar MA, Park SB, Vucic S. et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol 2017; 81 (03) 355-368 DOI: 10.1002/ana.24864.
    CrossrefPubMedGoogle Scholar
  • 3 Mercuri E, Lucibello S, Perulli M. et al. Longitudinal natural history of type I spinal muscular atrophy: a critical review. Orphanet J Rare Dis 2020; 15 (01) 84 DOI: 10.1186/s13023-020-01356-1.
    CrossrefPubMedGoogle Scholar
  • 4 Farrar MA, Kiernan MC. The genetics of spinal muscular atrophy: progress and challenges. Neurotherapeutics 2015; 12 (02) 290-302 DOI: 10.1007/s13311-014-0314-x.
    CrossrefPubMedGoogle Scholar
  • 5 Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care. J Neuromuscul Dis 2020; 7 (01) 1-13 DOI: 10.3233/JND-190424.
    CrossrefPubMedGoogle Scholar
  • 6 Pane M, Coratti G, Sansone VA. et al; Italian EAP Working Group. Type I SMA “new natural history”: long-term data in nusinersen-treated patients. Ann Clin Transl Neurol 2021; 8 (03) 548-557 DOI: 10.1002/acn3.51276.
    CrossrefPubMedGoogle Scholar
  • 7 Darras BT, Masson R, Mazurkiewicz-Bełdzińska M. et al; FIREFISH Working Group. Risdiplam-treated infants with Type 1 spinal muscular atrophy versus historical controls. N Engl J Med 2021; 385 (05) 427-435 DOI: 10.1056/NEJMoa2102047.
    CrossrefPubMedGoogle Scholar
  • 8 Mercuri E, Finkel RS, Muntoni F. et al; SMA Care Group. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 2018; 28 (02) 103-115 DOI: 10.1016/j.nmd.2017.11.005.
    CrossrefPubMedGoogle Scholar
  • 9 Finkel RS, Mercuri E, Meyer OH. et al; SMA Care group. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord 2018; 28 (03) 197-207 DOI: 10.1016/j.nmd.2017.11.004.
    CrossrefPubMedGoogle Scholar
  • 10 Pierzchlewicz K, Kępa I, Podogrodzki J, Kotulska K. Spinal muscular atrophy: The use of functional motor scales in the era of disease-modifying treatment. Child Neurol Open 2021;8:2329048X211008725
    Google Scholar
  • 11 Bach JR, Saltstein K, Sinquee D, Weaver B, Komaroff E. Long-term survival in Werdnig-Hoffmann disease. Am J Phys Med Rehabil 2007; 86 (05) 339-345 , quiz 346–348, 379 DOI: 10.1097/PHM.0b013e31804a8505.
    CrossrefPubMedGoogle Scholar
  • 12 Bach JR, Gupta K, Reyna M, Hon A. Spinal muscular atrophy type 1: Prolongation of survival by noninvasive respiratory aids. Pediatr Asthma Allergy Immunol 2009; 22 (04) 151-161 DOI: 10.1089/pai.2009.0002.
    CrossrefGoogle Scholar
  • 13 Glanzman AM, Mazzone E, Main M. et al. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord 2010; 20 (03) 155-161 DOI: 10.1016/j.nmd.2009.11.014.
    CrossrefPubMedGoogle Scholar
  • 14 Glanzman AM, McDermott MP, Montes J. et al; Pediatric Neuromuscular Clinical Research Network for Spinal Muscular Atrophy (PNCR), Muscle Study Group (MSG). Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Pediatr Phys Ther 2011; 23 (04) 322-326 DOI: 10.1097/PEP.0b013e3182351f04.
    CrossrefPubMedGoogle Scholar
  • 15 Finkel R, Bertini E, Muntoni F, Mercuri E. 209th ENMC International Workshop: Outcome measures and clinical trial readiness in spinal muscular atrophy 7–9 November 2014, Heemskerk, The Netherlands. Neuromuscul Dis 2015; 25 (07) 593-602 DOI: 10.1016/j.nmd.2015.04.009.
    CrossrefPubMedGoogle Scholar
  • 16 Glanzman AM, Mazzone ES, Young SD. et al. Evaluator Training and Reliability for SMA Global Nusinersen Trials1. J Neuromuscul Dis 2018; 5 (02) 159-166 DOI: 10.3233/JND-180301.
    CrossrefPubMedGoogle Scholar
  • 17 Iwabe C, Miranda-Pfeilsticker BH, Nucci A. Medida da função motora: versão da escala para o português e estudo de confiabilidade. Rev Bras Fisioter. 2008; 12 (05) 417-424 DOI: 10.1590/S1413-35552008000500012.
    CrossrefGoogle Scholar
  • 18 Corre MT. Tradução e adaptação cultural dos instrumentos: Hammersmith Neonatal Neurological Assessment (HNNE) e Hammersmith Infant Neurological Assessment (HINE) e validação do instrumento HNNE para lactentes brasileiros com risco de paralisia cerebral [Thesis]. São Paulo: Universidade de Medicina de Ribeirão Preto; 2020
    Google Scholar
  • 19 Reichenheim ME, Moraes CL. [Operationalizing the cross-cultural adaptation of epidemiological measurement instruments]. Rev Saude Publica 2007; 41 (04) 665-673 DOI: 10.1590/s0034-89102006005000035.
    CrossrefPubMedGoogle Scholar
  • 20 Fortes CPDD, Araújo APQC. Check list for healthcare questionnaires cross-cultural translation and adaptation. Cad Saude Colet 2019; 27 (02) 202-209 DOI: 10.1590/1414-462X201900020002.
    CrossrefGoogle Scholar
  • 21 Mokkink LB, Terwee CB, Patrick DL. et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol 2010; 63 (07) 737-745 DOI: 10.1016/j.jclinepi.2010.02.006.
    CrossrefPubMedGoogle Scholar
  • 22 Souza AC, Alexandre NMC, Guirardello EB. Psychometric properties in instruments evaluation of reliability and validity. Epidemiol Serv Saude 2017; 26 (03) 649-659 DOI: 10.5123/S1679-49742017000300022.
    CrossrefPubMedGoogle Scholar
  • 23 Borsa JC, Damásio BF, Bandeira DR. Cross-cultural adaptation and validation of psychological instruments: Some considerations. Paideia. 2012; Sep; 22 (53) 423-432 DOI: 10.1590/1982-43272253201314.
    CrossrefGoogle Scholar
  • 24 Alexandre NMC, Coluci MZO. [Content validity in the development and adaptation processes of measurement instruments]. Cien Saude Colet 2011; 16 (07) 3061-3068 DOI: 10.1590/s1413-81232011000800006.
    CrossrefPubMedGoogle Scholar
  • 25 Alexandre NMC, Gallasch CH, Lima MHM, Rodrigues RCM. Reliability in the development and evaluation of measurement instruments in the health field. Rev Eletr Enf 2013; 15 (03) 802-809 DOI: 10.5216/ree.v15i3.20776.
    CrossrefGoogle Scholar
  • 26 Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 2016; 15 (02) 155-163 DOI: 10.1016/j.jcm.2016.02.012.
    Google Scholar
  • 27 Hjartarson HT, Nathorst-Böös K, Sejersen T. Disease modifying therapies for the management of children with Spinal Muscular Atrophy (5q SMA): An update on the emerging evidence. Drug Des Devel Ther 2022; 16: 1865-1883 DOI: 10.2147/DDDT.S214174.
    CrossrefPubMedGoogle Scholar
  • 28 Russman BS, Iannaccone ST, Samaha FJ. A phase 1 trial of riluzole in spinal muscular atrophy. Arch Neurol 2003; 60 (11) 1601-1603 DOI: 10.1001/archneur.60.11.1601.
    CrossrefPubMedGoogle Scholar
  • 29 Blaschek A, Hesse N, Warken B. et al. Quantitative motion measurements based on markerless 3D full-body tracking in children with SMA highly correlate with standardized motor assessments. J Neuromuscul Dis 2022; 9 (01) 121-128 DOI: 10.3233/JND-200619.
    CrossrefPubMedGoogle Scholar
  • 30 Edel L, Grime C, Robinson V. et al. A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs. Neuromuscul Disord 2021; 31 (04) 300-309 DOI: 10.1016/j.nmd.2021.01.008.
    CrossrefPubMedGoogle Scholar
  • 31 Bach JR, Gonçalves MR, Hamdani I, Winck JC. Extubation of patients with neuromuscular weakness: a new management paradigm. Chest 2010; 137 (05) 1033-1039 DOI: 10.1378/chest.09-2144.
    CrossrefPubMedGoogle Scholar
  • 32 Fauroux B, Khirani S. Neuromuscular disease and respiratory physiology in children: putting lung function into perspective. Respirology 2014; 19 (06) 782-791 DOI: 10.1111/resp.12330.
    CrossrefPubMedGoogle Scholar